Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)Validation of the Geriatric Vulnerability Score (GVS) in older ovarian cancer (oOC) patients: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study S. Banerjee: Honoraria (self), Research grant / Funding (self): AstraZeneca; Honoraria (self): Tesaro; Honoraria (self): Clovis Oncology; Honoraria (self): Merck; Honoraria (self): PharmaMar; Honoraria (self): Roche; Honoraria (self): Seattle Genetics; Honoraria (self): Nucana. Abstract
Following are highlights of breast cancer advances. The hope is that we can obtain more data and start to narrow this down.
The nice part about breast cancer is that we have two PARP inhibitors, both olaparib and talazoparib that are active in metastatic BRCA1 and 2 breast cancer. Abstract ESMO 2019 Congress Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC) Date Median PFS and DoR for pts with fewer prior lines of chemotherapy was not yet reached, suggesting that these pts may derive a greater benefit from the combination. Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola) – Phase III SOLO1 trial
P. Herbolsheimer: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.For more detailed information on the cookies we use, please check our Necessary cookies enable core functionality. The CR rate was higher than anticipated. PARP inhibitors for metastatic breast cancer P. Roxburgh: Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Research grant / Funding (institution), Travel / Accommodation / Expenses: Tesaro. V. Rocher Ros: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany Five pts discontinued olaparib and three discontinued durvalumab due to an adverse event.
Prof Susan Domchek speaks to ecancer at ESMO 2019 in Barcelona about a phase II study of olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer. Abstract Although these drugs are terrific and in both studies showed improvement in quality of life compared to standard chemotherapy, the progression free survival is not as long as we’d like, resistance mechanisms developed. 1,2 MEDIOLA is a phase I/II open-label, multicenter study evaluating the combination of … Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA The response rate was 63% but there were some encouraging signals in terms of duration of response, that is once you have a response that it’s possible that it could be prolonged in combination with durvalumab. K. Meyer: Shareholder / Stockholder / Stock options, Full / Part-time employment: AstraZeneca. Again, this was a heterogeneous population, it allowed for more lines of therapy. There’s a lot of work with combinations, so this is one example – a combination of a PARP inhibitor with immunotherapy – but there are a lot of other combinations that are being studied to see whether we can do better with what we’ve got right now. With the data cut-off on 1 Nov 2018, 28% pts were still on treatment. Median OS for all pts was not yet reached, with 87.0% of pts alive at 24 months (median follow up = 20.4 months). 10.1093/annonc/mdz253 H.K.
Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA All funding for this site is provided directly by ESMO. A. Lortholary: Honoraria (self): AstraZeneca; Honoraria (self): Tesaro. This study works on the rationale of the OLYMPIAD trial results which showed a good response rate for olaparib, hopefully an immune checkpoint inhibitor would expand the duration of response and improve PFS. Prof Tony Mok - Chinese University of Hong Kong, Hong Kong The updated data were featured in two separate presentations at the 2019 ESMO Congress.
We also don’t know the best biomarkers. Secondary endpoints were 28-wk DCR, objective response rate (ORR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and biomarker analyses.Thirty-two/thirty-four pts treated were eligible. ESMO 2019 Congress Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC) Date The rationale behind this is that we know that there are high response rates to olaparib in BRCA1 and 2 breast cancer, the OlympiAD trial showed a 60% response rate. Dr Katie Kelley - University of California San Francisco, San Francisco, USA R.H. Alvarez: Honoraria (self): Eisai; Honoraria (self): Puma; Leadership role: Cancer Treatment Center of America. Cisplatin plus/minus veliparib in metastatic TNBC and/or germline BRCA-associate... Prof Sanjay Popat - The Royal Marsden Hospital, London, UK Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive pa... So that’s one clear area.
It’s a relatively small trial with 34 patients. Similar … PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural m... S. Domchek: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Clovis Oncology; Honoraria (self): Bristol-Myers Squibb; Research grant / Funding (institution): PharmaMar. The content on this site is intended for healthcare professionals only